Aimmune Therapeutics, Inc. (NASDAQ:AIMT) – Investment analysts at Cantor Fitzgerald issued their FY2019 earnings per share (EPS) estimates for Aimmune Therapeutics in a research note issued to investors on Monday. Cantor Fitzgerald analyst W. Tanner forecasts that the biotechnology company will post earnings of ($2.17) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $55.00 price objective on the stock.
Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.09.
AIMT has been the subject of several other reports. Piper Jaffray Companies set a $38.00 price target on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a report on Saturday, October 21st. Wedbush restated an “outperform” rating and set a $70.00 price target on shares of Aimmune Therapeutics in a report on Friday, December 1st. Zacks Investment Research upgraded shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $34.00 price target for the company in a report on Wednesday, November 8th. Roth Capital started coverage on shares of Aimmune Therapeutics in a report on Monday, November 20th. They set a “buy” rating and a $60.00 price target for the company. Finally, ValuEngine cut shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. Aimmune Therapeutics has a consensus rating of “Buy” and a consensus target price of $55.43.
Aimmune Therapeutics (NASDAQ:AIMT) traded up $1.11 during mid-day trading on Thursday, hitting $38.02. 557,522 shares of the company traded hands, compared to its average volume of 414,530. The firm has a market capitalization of $1,930.00 and a PE ratio of -16.25. Aimmune Therapeutics has a twelve month low of $15.97 and a twelve month high of $40.00.
In related news, CEO Stephen George Dilly sold 1,154 shares of the firm’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $26.24, for a total transaction of $30,280.96. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Douglas T. Sheehy sold 1,905 shares of the firm’s stock in a transaction that occurred on Thursday, November 9th. The shares were sold at an average price of $33.00, for a total transaction of $62,865.00. Following the transaction, the insider now directly owns 1,905 shares in the company, valued at approximately $62,865. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 136,298 shares of company stock worth $4,929,669. Insiders own 24.56% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. GSA Capital Partners LLP bought a new position in shares of Aimmune Therapeutics in the second quarter valued at approximately $442,000. Goldman Sachs Group Inc. raised its position in shares of Aimmune Therapeutics by 139.9% in the second quarter. Goldman Sachs Group Inc. now owns 227,377 shares of the biotechnology company’s stock valued at $4,675,000 after purchasing an additional 132,603 shares during the period. Point72 Asset Management L.P. raised its position in shares of Aimmune Therapeutics by 10.2% in the third quarter. Point72 Asset Management L.P. now owns 1,098,087 shares of the biotechnology company’s stock valued at $27,222,000 after purchasing an additional 101,855 shares during the period. Bank of New York Mellon Corp raised its position in shares of Aimmune Therapeutics by 16.9% in the second quarter. Bank of New York Mellon Corp now owns 131,353 shares of the biotechnology company’s stock valued at $2,700,000 after purchasing an additional 19,016 shares during the period. Finally, Citadel Advisors LLC bought a new position in shares of Aimmune Therapeutics in the second quarter valued at approximately $360,000. 73.34% of the stock is currently owned by hedge funds and other institutional investors.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.